TY - JOUR
T1 - Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic
AU - Ianiro, Gianluca
AU - Mullish, Benjamin H.
AU - Kelly, Colleen R.
AU - Kassam, Zain
AU - Kuijper, Ed J.
AU - Ng, Siew C.
AU - Iqbal, Tariq H.
AU - Allegretti, Jessica R.
AU - Bibbo', Stefano
AU - Sokol, Harry
AU - Zhang, Faming
AU - Fischer, Monika
AU - Costello, Samuel Paul
AU - Keller, Josbert J.
AU - Masucci, Luca
AU - Van Prehn, Joffrey
AU - Quaranta, Gianluca
AU - Quraishi, Mohammed Nabil
AU - Segal, Jonathan
AU - Kao, Dina
AU - Satokari, Reetta
AU - Sanguinetti, Maurizio
AU - Tilg, Herbert
AU - Gasbarrini, Antonio
AU - Cammarota, Giovanni
PY - 2020
Y1 - 2020
N2 - The COVID-19 pandemic has led to an exponential
increase in SARS-CoV-
2 infections and associated deaths,
and represents a significant challenge to healthcare
professionals and facilities. Individual countries have
taken several prevention and containment actions to
control the spread of infection, including measures
to guarantee safety of both healthcare professionals
and patients who are at increased risk of infection
from COVID-19. Faecal microbiota transplantation
(FMT) has a well-established
role in the treatment
of Clostridioides difficile infection. In the time of the
pandemic, FMT centres and stool banks are required
to adopt a workflow that continues to ensure reliable
patient access to FMT while maintaining safety and
quality of procedures. In this position paper, based on the
best available evidence, worldwide FMT experts provide
guidance on issues relating to the impact of COVID-19
on FMT, including patient selection, donor recruitment
and selection, stool manufacturing, FMT procedures,
patient follow-up
and research activities.
AB - The COVID-19 pandemic has led to an exponential
increase in SARS-CoV-
2 infections and associated deaths,
and represents a significant challenge to healthcare
professionals and facilities. Individual countries have
taken several prevention and containment actions to
control the spread of infection, including measures
to guarantee safety of both healthcare professionals
and patients who are at increased risk of infection
from COVID-19. Faecal microbiota transplantation
(FMT) has a well-established
role in the treatment
of Clostridioides difficile infection. In the time of the
pandemic, FMT centres and stool banks are required
to adopt a workflow that continues to ensure reliable
patient access to FMT while maintaining safety and
quality of procedures. In this position paper, based on the
best available evidence, worldwide FMT experts provide
guidance on issues relating to the impact of COVID-19
on FMT, including patient selection, donor recruitment
and selection, stool manufacturing, FMT procedures,
patient follow-up
and research activities.
KW - FMT, Clostridioides difficile, microbiota
KW - FMT, Clostridioides difficile, microbiota
UR - http://hdl.handle.net/10807/209668
U2 - 10.1136/gutjnl-2020-321829
DO - 10.1136/gutjnl-2020-321829
M3 - Article
SN - 0710-5843
SP - 1555
EP - 1563
JO - GUT
JF - GUT
ER -